Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Sectornieuws - biotech

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,743 14 jun 2024 17:35
  • -0,007 (-1,00%) Dagrange 0,743 - 0,759
  • 2.937.440 Gem. (3M) 6,2M

Sectornieuws - biotech

6.458 Posts
Pagina: «« 1 ... 153 154 155 156 157 ... 323 »» | Laatste | Omlaag ↓
  1. [verwijderd] 1 november 2016 15:29
    Als je de commentaren leest is Cinryze niet het enige probleem zouden ze hun hand overspeelt hebben.
    mooi wel want Pharming komt niet in handen van de Ierse veelvraat op deze manier.

    Shire PLC cut its full-year guidance and reported a net loss in the three months to Sept. 30, both because of heavy spending on the integration of its $32 billion acquisition of Baxalta Inc.

    Ze duikelen aardig naar beneden.

    Ruud..
  2. forum rang 10 voda 1 november 2016 16:06
    Pfizer boekt meer omzet bij stabiele winstvorming

    Outlook omzet verhoogd, outlook winst licht verlaagd.

    (ABM FN-Dow Jones) Pfizer heeft in het derde kwartaal een hogere omzet, terwijl de aangepaste winst stabiel bleef. Dit meldde de Amerikaanse farmareus dinsdagmiddag.

    De verbeterde omzet was voor een deel te danken aan de bijdrage van Hospira, dat Pfizer in september vorig jaar overnam. Het concern uit New York gaf toen al aan te verwachten dat de overgenomen activiteiten in het eerste jaar na de afronding van de transactie direct zouden bijdragen aan de winst per aandeel.

    De omzet nam met 8 procent toe van 12.087 miljoen dollar naar 13.045 miljoen dollar. In het derde kwartaal bleef de aangepaste winst bleef liggen en kwam uit op ruim 3.726 miljoen dollar. Per aandeel kwam de aangepaste winst 2 procent hoger uit op jaarbasis op 0,61 dollar.

    De overgenomen activiteiten van Hospira droegen voor 1.129 miljoen dollar bij aan de opbrengsten. Zonder Hospira steeg de omzet met 3 procent.

    Onder de streep resteerde wel een lagere nettowinst van 1.320 miljard dollar, tegenover 2.130 miljoen dollar in het derde kwartaal van 2015.

    Outlook

    Pfizer verhoogde dinsdag de outlook voor de omzet voor heel het jaar en verwacht nu een omzet van 52 miljard tot 53 miljard dollar. Eerder ging Pfizer uit van minimaal 51 miljard dollar aan omzet. De outlook voor de aangepaste winst per aandeel ligt nu op 2,38 tot 2,43 dollar tegen 2,48 dollar in een eerdere verwachting. De kosten voor research en development werd aangepast naar 7,8 miljard tot 8,1 miljard dollar. Eerder lag de range tussen 7,4 miljard en 7,8 miljard dollar.

    Het aandeel noteerde in de elektronische handel in Amerika vanmiddag 1,0 procent lager op 31,40 dollar.

    Door: ABM Financial News.

    info@abmfn.nl

    Redactie: +31(0)20 26 28 999

    Copyright ABM Financial News. All rights reserved

    (END) Dow Jones Newswires
  3. [verwijderd] 1 november 2016 21:29
    Valeant 35% in de plus

    Valeant jumps on news on potential Salix sale for $10B; shares up 16%
    www.seekingalpha.com/news/3219240

    • Battered and bruised Valeant Pharmaceuticals (VRX +16.3%) shows some life. Shares are up on increased volume in response to the news that the company is in talks to sell its Salix unit to Takeda (OTCPK:TKPHF)(OTCPK:TKPYY) for $10B.
    • Valeant bought Salix last year for $158 per share which valued Salix at $14.5B at the time.
    • If the transaction goes through, it will go a long way towards easing Valeant's $30B debt burden.
  7. forum rang 10 voda 2 november 2016 18:46
    MDxHealth wil 15 miljoen euro ophalen

    Ruim 4,5 miljoen nieuwe aandelen.

    (ABM FN) MDxHealth zal maximaal ruim 4,5 miljoen nieuwe aandelen uitgeven om zo 15 miljoen euro aan vers kapitaal op te halen. Dit maakte het Belgisch-Nederlandse biofarmabedrijf woensdag nabeurs bekend.

    De opbrengsten van de private plaatsing zal MDxHealth vooral gebruiken voor de marketing en verkoop in Amerika van de behandelingen ConfirmMDx en SelectMDx en het vermarkten van SelectMDx in Europa en de rest van de wereld.

    Ook wil het bedrijf de opbrengst gebruiken om de blaaskankertest AssureMDx sneller te ontwikkelen.

    Eind september bedroeg de kaspositie van MDxHealth 15,1 miljoen dollar. Bij de halfjaarcijfers was dit nog iets meer dan 20 miljoen dollar.

    De uitgifte van iets meer dan 4,5 miljoen nieuwe aandelen is krap 10 procent van het huidige aantal uitstaande aandelen.

    Het aandeel MDxHealth sloot woensdag, op een rode beurs, 0,3 procent hoger op 4,63 euro.

    Door: ABM Financial News.

    pers@abmfn.be

    Redactie: +32(0)78 486 481

    Copyright ABM Financial News. All rights reserved

    (END) Dow Jones Newswires
  8. [verwijderd] 3 november 2016 09:50
    November 2, 2016
    NEW GUIDANCE HELPS PHYSICIANS DIAGNOSE, MANAGE HEREDITARY ANGIOEDEMA
    October 28, 2016

    By Reuters Staff
    NEW YORK (Reuters Health) - An expert panel has issued consensus recommendations for managing children with hereditary angioedema (HAE) due to C1 inhibitor deficiency.
    Developed by the U.S. Hereditary Angioedema Association Medical Advisory Board and published online today in Pediatrics, the recommendations will help clinicians recognize and diagnose HAE, treat attacks and provide prophylaxis for children with HAE, the authors say.
    Led by Dr. Michael Frank of Duke Medical Center in Durham, North Carolina, the panel notes that HAE is a potentially life-threatening inherited disease characterized by attacks of skin swelling, severe abdominal pain, and upper airway swelling.
    The U.S. prevalence is unknown but is estimated at one per 50,000 population.
    HAE attacks usually begin in childhood, but the appropriate diagnosis is often missed, the panel notes.
    Once an accurate diagnosis is made, due to the complex and variable nature of HAE and treatment, the panel "strongly" recommends that every patient with HAE be followed by a physician who is knowledgeable about the condition and experienced in managing patients with HAE. This physician should work with the patient's primary care provider and the local community emergency department or hospital to ensure that components of the treatment plan are clearly communicated.
    The panel also advises educating patients and families about HAE and testing all first-degree family members for HAE, "given the demonstrated mortality risk associated with undiagnosed HAE and the fact that in some patients, manifestations of HAE may appear late in life."
    As for treatment, HAE attacks do not respond to epinephrine, antihistamines, or glucocorticoids, but with "recent understanding of pathophysiology, new and highly effective drugs have been developed," the panel notes.
    Therapeutic approaches for HAE include both acute on-demand therapy, given at the onset of symptoms to abrogate attacks, and prophylactic treatment to prevent or minimize the number and severity of attacks.
    Drugs currently approved by the U.S. Food and Drug Administration for prophylaxis are Cinryze, danazol, and tranexamic acid. For acute on demand treatment, options are Berinert, Ruconest, Icatibant, and fresh frozen plasma.
    "Patients should have a management plan in place, with easy access to their health care provider during an attack. The management plan should include the names and dosages of the medications and the methods of administration," the panel says.
    Monitoring attack frequency and severity is equally important, the panel says.
    "HAE disease severity is highly variable, both between patients and also over time in an individual patient. Patients may be symptom free for years and then begin to have attacks. Therefore, physician knowledge of the patient's attack frequency, severity, and factors that precipitate attacks are critical to successful HAE management," they write.
    The panel recommends that patients or families keep a record of all attacks, regardless of severity (mild, moderate, or severe). These records should include a description of the attack including location and severity, treatment of attack, and response to treatment.
    "The treating pediatrician with detailed knowledge of the patient and family, attack frequency, precipitating factors, current drugs available, and response to therapy can achieve effective disease control in most children, allowing them to achieve a normal life," the panel concludes.
  10. [verwijderd] 3 november 2016 20:54
    Generic drugmakers plunge as DOJ charges could come soon
    www.seekingalpha.com/news/3220739

    • The DOJ could file charges before the end of the year in its probe over whether companies colluded on drug pricing, according to Bloomberg.
    • Among those hit: Mylan (MYL -7.4%), Teva (TEVA -10.6%), and Endo International (ENDP -15.4%).
    • Others include Allergan (AGN -4.1%) and Valeant (VRX -6.9%)
    • Related ETFs: IBB, XLV, IYH, XBI, VHT, PJP, BBH, HQH, FBT, CURE, HQL, XPH, PBE, FXH, FHLC, IHE, RXL
  11. [verwijderd] 3 november 2016 20:59
    quote:

    lower schreef op 3 november 2016 20:54:

    Generic drugmakers plunge as DOJ charges could come soon
    www.seekingalpha.com/news/3220739

    • The DOJ could file charges before the end of the year in its probe over whether companies colluded on drug pricing, according to Bloomberg.
    • Among those hit: Mylan (MYL -7.4%), Teva (TEVA -10.6%), and Endo International (ENDP -15.4%).
    • Others include Allergan (AGN -4.1%) and Valeant (VRX -6.9%)
    • Related ETFs: IBB, XLV, IYH, XBI, VHT, PJP, BBH, HQH, FBT, CURE, HQL, XPH, PBE, FXH, FHLC, IHE, RXL
    www.bloomberg.com/news/articles/2016-...
  12. [verwijderd] 4 november 2016 15:11
    Sanofi Genzyme launches late-stage study of second-generation enzyme replacement therapy for Pompe disease

    • Sanofi's (NYSE:SNY) Genzyme unit commences a Phase 3 clinical trial, COMET, assessing its second-generation enzyme replacement therapy NeoGAA for the treatment of Pompe disease, a rare inherited disorder caused by the buildup of glycogen in cells due to a malfunctioning enzyme called acid alpha-glucosidase (GAA).

    • COMET will randomize 96 subjects to receive either NeoGAA (GZ402666) or alglucosidase alfa (Lumizyme) every two weeks during the 49-week treatment period. A 96-week open-label treatment period will follow. The primary endpoint is the change from baseline to Month 12 in percent predicted forced vital capacity in an upright position. According to ClinicalTrials.gov, the estimated study completion date is August 2020.

    • NeoGAA has been designed for enhanced receptor targeting and enzyme uptake via greater affinity for the M6P receptors on muscle cells thereby enhancing glycogen clearance and improving clinical efficacy compared to alglucosidase alfa.


    ====

    Grote broer van Pharming
    www.pharming.com/glossary/
    Fabry’s disease

    Fabry’s disease is a rare, genetic lysosomal storage disease typically occurring in male children. A deficiency in the alpha-galactosidase A (GLA) enzyme leads to excessive deposition of glycosphingolipids in endothelium, epithelium and smooth muscle cells. The progressive accumulation of glycosphingolipids in the lining of the blood vessels accounts for the associated clinical abnormalities of skin, eyes, kidneys, heart, brain and peripheral nervous system. Disease progression varies, but ultimately the disease is fatal.

    Gaucher’s disease
    Gaucher’s disease is a genetic disease in which fatty substances (sphingolipids) accumulate in cells and certain organs. It is caused by a hereditary deficiency of the enzyme beta-glucocerebrosidase (GCase). When the enzyme is defective, glucosylceramide can collect in the spleen, liver, kidneys, lungs, brain, and bone marrow. The severity of the disease varies, but it is ultimately fatal.

    Pompe disease
    Glycogen-storage disease type II (GSDII), also referred to as Pompe disease, is one of the rare, genetic lysosomal storage diseases. It results from the deficiency of alpha-glucosidase (GAA), leading to accumulation of glycogen in organs, particularly skeletal and respiratory muscles, liver and nerves. In the infantile onset form, also the muscles in the heart are affected. This form is marked by a progressive and rapidly fatal course. Juvenile and adult-onset forms are less progressive and typically not accompanied by cardiac disease. These patients experience muscle weakness and ultimately succumb to respiratory failure.

    ===============

    De Vries heeft al aangegeven dat er een lead molecule is voor fabry.
  13. [verwijderd] 7 november 2016 15:19
    Kleine broer van Valeant (groei op acquisitie)

    Concordia Q3 top line up 100%; non-GAAP earnings down 26%; shares down 21% premarket
    www.seekingalpha.com/news/3221664
    • Concordia International (NASDAQ:CXRX) Q3 results ($M): Revenues: 185.5 (+99.5%).
    • Net Income (continuing ops): (75.1) (-999%); Non-GAAP Net Income: 35.6 (-26.1%); EBITDA: 30.2 (-43.4%); Non-GAAP EBITDA: 104.4 (+46.2%); EPS: (1.47) (-999%); Non-GAAP EPS: 0.69 (-49.6%).
    • Consensus view was non-GAAP EPS of $1.04 on revenues of $206M.
    • No guidance given.
    • Allan Oberman appointed as new CEO, Jordan Kupinsky as new Chairman.
    • Shares are down 21% premarket on average volume.

  14. [verwijderd] 8 november 2016 14:52
    Valeant Pharmaceuticals Q3 sales down 11%; non-GAAP earnings down 36%; cash flow ops down 22%; guidance lowered; shares down 7% premarket
    seekingalpha.com/news/3222143-valeant...

    ===========
    Valeant Pharmaceuticals International, Inc. (VRX) Pre-Market Trading
    VRX
    $15.65
    *
    -3.48
    -18.19%

    *Delayed - data as of 11/08/2016 08:4
    Read more: www.nasdaq.com/symbol/vrx/premarket#i...
    ===============
    Valeant Pharmaceuticals International, Inc. 2016 Q3 - Results - Earnings Call Slides
    seekingalpha.com/article/4021020-vale...
    =============

    11/08/16 Valeant Q3 2016 Earnings
    ir.valeant.com/~/media/Files/V/Valean...
  15. [verwijderd] 9 november 2016 11:55
    Healthcare on the move?
    seekingalpha.com/news/3222590-healthc...
    Healthcare stocks, the weakest sector this year, may become winners, as Obamacare reforms are set to be "repealed and replaced" and major legislation Clinton proposed is unlikely to be imposed on drugmakers.

    While Trump hasn't set out a comprehensive alternative to the Affordable Care Act (which may see 22M Americans lose current coverage), he said he'll encourage competition between markets in different states.

    Insurance stocks: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY

    Drugmakers premarket: MYL +5.8%, NVS +3.4%, SNY +2.9%, AZN +2.4%, GSK +1.9%, PFE +1.8%, CELG +1%, ABBV, MRK, BMY, LLY, JNJ, ABT, ACET, ZTS, BIIB, REGN

    #Election2016
  16. [verwijderd] 9 november 2016 14:03
    CTI BioPharma Reports Third Quarter 2016 Financial Results


    News provided by
    CTI BioPharma Corp. ?
    Nov 08, 2016, 16:01 ET

    SEATTLE, Nov. 8, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the third quarter ended September 30, 2016.

    "We recently reported top-line data from our second Phase 3 trial of pacritinib and are encouraged by its clinical profile, particularly in patients with severe thrombocytopenia, and look forward to the presentation of the full results at an upcoming scientific meeting," said Richard Love, Interim President and CEO of CTI BioPharma. "With this data in hand, our top priority is to work with the FDA in short order to seek to address their recommendations for getting pacritinib off clinical hold and back on a development track. This has been a challenging year for us; however, we are committed to bringing novel therapies to patients with a critical unmet medical need."


    Recent Events
    •In August 2016, the Company announced top-line results from the PERSIST-2 randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT) for the treatment of patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter. Preliminary results demonstrated that the PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in spleen volume reduction in patients with myelofibrosis treated with pacritinib compared to BAT, including the approved JAK2 inhibitor ruxolitinib (p<0.01). Although the PERSIST-2 trial did not meet the other co-primary endpoint of greater than 50 percent reduction in Total Symptom Score (TSS), the preliminary analysis approached marginal significance compared to BAT (p=0.0791).
    •In October 2016, the Company regained worldwide rights for the development and commercialization of pacritinib following termination of the Pacritinib License Agreement with Baxalta, which is now part of Shire plc. Under the terms of the Asset Return and Termination Agreement with Baxalta, the Company has received $10.3 million from Shire as reimbursement for certain expenses incurred or to be incurred. The Company in exchange has agreed to provide a one-time payment to Baxalta, upon the first regulatory approval or any pricing and reimbursement approvals of a product containing pacritinib, in the amount of approximately $10.3 million which represents certain amounts paid by Baxalta for the benefit of the pacritinib program manufacturing efforts.
    •In October 2016, the Company announced that James A. Bianco, M.D. retired from his position as President and Chief Executive Officer. At the request of the Board of Directors, Richard Love, a director of the Company since 2007, was appointed to serve as Interim President and Chief Executive Officer. Mr. Love started two biotechnology companies, Triton Biosciences Inc. and ILEX Oncology Inc., and he served as Chief Executive Officer for Triton Biosciences Inc. from 1983 to 1991 and as Chief Executive Officer for ILEX Oncology from 1994 to 2001. Mr. Love also served in executive positions at not-for-profit organizations including the Cancer Therapy and Research Center (CTRC) and the Translational Genomics Research Institute (TGen).

    Third Quarter Financial Results

    Total revenues for the third quarter and nine months ended September 30, 2016, were $4.4 million and $48.3 million, respectively, compared to $1.0 million and $4.8 million for the respective periods in 2015. The increase in total revenue for the nine month period in 2016 is primarily due to recognition of $32 million in milestone payments and reimbursement of development costs from Shire plc related to pacritinib. CTI BioPharma had previously received a cash advance for these milestone payments from Baxalta in the second quarter of 2015 that was accounted for as long-term debt until the achievement of the associated milestones in the first quarter of 2016. Net product sales of PIXUVRI for the third quarter and the nine months ended September 30, 2016, were $1.0 million and $3.3 million, respectively, compared to $0.7 million and $2.4 million for the respective periods in 2015.

    GAAP operating loss for the third quarter and nine months ended September 30, 2016, was $28.7 million and $43.6 million, respectively, compared to GAAP operating loss of $32.0 million and $90.5 million for the respective periods in 2015. Non-GAAP operating loss, which excludes non-cash share-based compensation expense, for the third quarter and nine months ended September 30, 2016, was $23.6 million and $32.4 million, respectively, compared to the non-GAAP operating loss of $26.1 million and $77.5 million for the respective periods in 2015. Non-cash share-based compensation expense for the third quarter and nine months ended September 30, 2016, was $5.1 million and $11.2 million, respectively, compared to $5.9 million and $13.0 million for the respective periods in 2015. For information on CTI BioPharma's use of non-GAAP operating loss and a reconciliation of such measure to GAAP operating loss, see the section below entitled "Non-GAAP Financial Measures."

    Net loss for the third quarter of 2016 was $29.2 million, or ($0.10) per share, compared to a net loss of $32.6 million, or ($0.19) per share, for the same period in 2015. Net loss for the nine months ended September 30, 2016, was $45.6 million, or ($0.16) per share, compared to a net loss of $93.8 million, or ($0.54) per share, for the same period in 2015. The decrease in net loss for the third quarter and the nine months ended September 30, 2016, compared to the respective periods in 2015 is primarily due to increased net product sales and license and contract revenue.

    As of September 30, 2016, cash and cash equivalents totaled $61.6 million, compared to $128.2 million at December 31, 2015.

    www.prnewswire.com/news-releases/cti-...
  17. forum rang 10 DeZwarteRidder 10 november 2016 16:09
    ProMIS Neurosciences initiates Cohort Study
    Stockhouse Editorial

    ProMIS Neurosciences Inc (TSX: PMN, OTCQB: ARFXF, Forum) announced today that it has commenced a groundbreaking Cohort Study intended to evaluate the prevalence of different strains of Amyloid beta (Ab)prions in patients with Alzheimer’s disease (AD). First results are anticipated in the first quarter of 2017.

    The Study is being conducted in the laboratories of the Company’s CSO, Dr. Neil Cashman. The study will employ cerebrospinal fluid samples of more than 100 patients with dementia, collected over an eight-year period by Dr. Robin Hsuing, Associate Professor of Neurology at the University of British Columbia. The date accompanying these samples may also lead to the identification of prion strains which are associated with more rapid disease progression. Further information can be found here.

    ProMIS was recently in the news earlier this month when it announced five “novel” antibody targets which met the ideal target profile for Alzheimer’s disease.

    The Company has 181 million shares outstanding and a market cap of $25.4 million.

    .
  18. [verwijderd] 10 november 2016 17:00
    09:36:01 / 10-11-16 DJ ^Goede testresultaten blaaskankertest MDxHealth

    Een accuraatheid van 99 procent om blaaskanker uit te sluiten.
    (ABM FN) MDxHealth heeft bevredigende resultaten laten publiceren in the Journal of Urology in verband met haar blaaskankertest AssureMDx. Dat meldde het Belgisch-Nederlandse diagnosticabedrijf donderdag.
    Het gaat om een tweede klinische studie voor de test gebaseerd op urinestalen van 200 patiënten. Met deze test kan een uitgebreider onderzoek vermeden worden. De accuraatheid van de test voor een negatieve diagnose kwam op 99 procent uit.
    "Deze zeer positieve resultaten onderstrepen verder de klinische geldigheid en het nut van AssureMDx en de publicatie van deze gegevens zal de bèta lancering tijdens het vierde kwartaal in de Verenigde Staten ondersteunen, met een volledige lancering van de test in het begin van 2017," zo verklaarde CEO Jan Groen.
    Het aandeel MDxHealth handelde donderdag, kort na opening, 4,0 procent hoger op 4,75 euro.
    Door: ABM Financial News.
    pers@abmfn.be
    Redactie: +32(0)78 486 481
    Copyright ABM Financial News. All rights reserved
    (END) Dow Jones Newswires
    November 10, 2016 03:36 ET (08:36 GMT)
    © 2016 ABM Financial News. All rights reserved.

    AAND MDXHEALTH
    BE0003844611
  19. forum rang 10 voda 10 november 2016 20:50
    Omzetdaling voor AstraZeneca

    Gepubliceerd op 10 nov 2016 om 08:45 | Views: 2.737

    LONDEN (AFN) - De Britse farmaceut AstraZeneca heeft de omzet in het derde kwartaal zien dalen. Stevige concurrentie van generieke concurrentie voor cholesterolmedicijn Crestor was daar onder meer de oorzaak van, zo bleek donderdag.

    Wel wist AstraZeneca de schade enigszins in te perken door bijvoorbeeld ,,goede groei'' bij nieuwe gelanceerde producten. De opbrengsten zakten concreet met 4 procent ten opzichte van een jaar eerder, tot 5,7 miljard dollar. Analisten rekenden in doorsnee op een omzet van 5,9 miljard dollar.

    De kernwinst van de op een na grootste farmaceut van het Verenigd Koninkrijk profiteerde van een eenmalige belastingmeevaller. Dat resultaat kwam mede daardoor uit op 1,32 dollar per aandeel, 28 procent meer dan een jaar eerder. Als de belastingmeevaller uit het cijfer wordt gehaald, bedroeg het resultaat 0,96 dollar per aandeel, iets onder de prognose van marktvorsers.

    AstraZeneca herhaalde woensdag zijn verwachtingen voor heel het jaar.
  20. forum rang 10 voda 10 november 2016 20:53
    Minder verlies voor biotechnoloog Probiodrug

    Gepubliceerd op 10 nov 2016 om 08:07 | Views: 3.756

    HALLE (AFN) - Biotechnologiebedrijf Probiodrug heeft in de eerste negen maanden van dit jaar minder verlies geleden ten opzichte van een jaar eerder. Dat meldde de in Amsterdam genoteerde Duitse onderneming donderdag.

    Het bedrijf, dat werkt aan geneesmiddelen tegen de ziekte van Alzheimer en nog geen omzet draait, boekte een verlies van ruim 8,4 miljoen euro. Vorig jaar kwam Probriodrug over de periode januari tot en met september onder de streep nog bijna 9,4 miljoen euro tekort. In het derde kwartaal kwam het verlies uit op 2,4 miljoen euro.

    Volgens topman Konrad Glund heeft de onderneming in het derde kwartaal ,,significante vooruitgang'' laten zien, zowel met zijn ontwikkelingsprogramma's als bedrijfsmatig. Het bedrijf had eind september 11,6 miljoen euro in kas. De uitgaven en kaspositie zijn in lijn met de verwachtingen van het management.
6.458 Posts
Pagina: «« 1 ... 153 154 155 156 157 ... 323 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

De markt kijkt niet verder dan zijn neus lang is bij Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 31 mei Slotcall: AEX struikelt voor de finish, maar Pharming komt met de schrik vrij
  2. 31 mei Tegenslag bij EMA resulteert in tijdverlies voor Pharming 1
  3. 30 mei Europese goedkeuring voor leniolisib van Pharming loopt vertraging op 1
  4. 21 mei Jaarvergadering Pharming akkoord met alle agendapunten 1
  5. 10 mei RBC verlaagt koersdoel Pharming
  6. 08 mei Update: Flinke omzetstijging Pharming 2
  7. 08 mei AEX houdt 900 punten waarschijnlijk niet vast, zorgen Ahold, Pharming en SBM voor spektakel? 2
  8. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  9. 18 apr Pharming rondt plaatsing obligaties af 5
  10. 18 apr Pharming vervangt converteerbare lening 6

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!